Inhibiting TRK Proteins in Clinical Cancer Therapy

Gene rearrangements resulting in the aberrant activity of tyrosine kinases have been identified as drivers of oncogenesis in a variety of cancers. The tropomyosin receptor kinase (TRK) family of tyrosine receptor kinases is emerging as an important target for cancer therapeutics. The TRK family cont...

Descripción completa

Detalles Bibliográficos
Autores principales: Lange, Allison M., Lo, Hui-Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5923360/
https://www.ncbi.nlm.nih.gov/pubmed/29617282
http://dx.doi.org/10.3390/cancers10040105

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5923360/
https://www.ncbi.nlm.nih.gov/pubmed/29617282
http://dx.doi.org/10.3390/cancers10040105

Ejemplares similares